<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713139</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-CLP-03(05/12)</org_study_id>
    <nct_id>NCT02713139</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Association of Clotrimazole and Metronidazole in the Treatment of Vaginal Discharge From Different Etiologies.</brief_title>
  <acronym>Frauen</acronym>
  <official_title>Phase III, Multicenter, Randomized, Parallel, Open Label, Controlled and Comparative Study to Evaluate the Efficacy and Safety of the Association of Clotrimazole 200mg and Metronidazole 0,75% (Colpistatin 5DT®) Compared to Gynecological Flagyl®(Metronidazole 100mg/g) and the Vaginal Cream Gino-Canesten® 3 (Clotrimazole 20mg/g) in the Syndromic Treatment of the Vaginal Discharge From Different Etiologies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ache Laboratorios Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ache Laboratorios Farmaceuticos S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of the association&#xD;
      clotrimazole 200mg and metronidazole 0,75%(Clopistatin 5DT®) and whether it is superior when&#xD;
      compared with metronidazole 100mg/g (gynecologic Flagyl®) and clotrimazole 20mg/g&#xD;
      (Gino-Canesten® 3) in the syndromic treatment of vaginal discharge from different etiologies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to budget limitations, the company decided to withdraw this study.&#xD;
  </why_stopped>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ceasing of the symptoms of vaginal discharge after 3(three) days of the end of the treatment</measure>
    <time_frame>From baseline to 3 days after the end of the treatment</time_frame>
    <description>Examination of the breasts and internal and external examination of the female genital organ.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Registry of Adverse Effects occurrence throughout the study</measure>
    <time_frame>From baseline to 30 days after the end of the treatment</time_frame>
    <description>Evaluation of Clinical and Physical examination and the measure of vital signs; Evaluation of Adverse effects; Evaluation of Laboratory exams; And evaluation of urine beta-hcg test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal microflora reconstitution through microbiological evaluation of vaginal material</measure>
    <time_frame>From baseline to 30 days after treatment's end</time_frame>
    <description>Evaluation of the collected vaginal material with the microbiological tests(Whiff, Gram, Affirm VPIII) and PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatology recurrence and/or vaginal microflora alteration 30 days after the treatment's end</measure>
    <time_frame>From baseline to 30 days after treatment's end</time_frame>
    <description>Examination of the breasts and internal and external examination of the female genital organ.&#xD;
Evaluation of the collected vaginal material with the microbiological tests(Whiff, Gram, Affirm VPIII) and PCR.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Sexual Active Women</condition>
  <condition>Vaginal Discharge</condition>
  <arm_group>
    <arm_group_label>Colpistatin 5DT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gynecological Flagyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gino-Canesten 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clotrimazole + Metronidazole</intervention_name>
    <description>Vaginal cream with Clotrimazole 200mg and Metronidazole 0,75%. Apply once per day, before bedtime, for 5 (five) days.</description>
    <arm_group_label>Colpistatin 5DT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Vaginal gel with Metronifdazole 100mg/g. Apply once per day, before bedtime, for 10(ten) days.</description>
    <arm_group_label>Gynecological Flagyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clotrimazole</intervention_name>
    <description>Vaginal cream with Clotrimazole 20mg/g. Apply once per day, before bedtime, for 3 (three) days.</description>
    <arm_group_label>Gino-Canesten 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects that have already started sexual activity;&#xD;
&#xD;
          -  Subjects with complaints of vaginal discharge and had not received treatment in the 30&#xD;
             days before the enrollment visit;&#xD;
&#xD;
          -  Subjects in the premenopausal period must be under usage of acceptable contraceptive&#xD;
             methods(oral contraceptive, injectable contraceptives, IUD, hormonal implant, hormone&#xD;
             transdermal adhesive, tubal ligation) or are surgically sterile (bilateral&#xD;
             oophorectomy or hysterectomy); or accept to utilize a barrier contraceptive provided&#xD;
             by the sponsor during the period of the study;&#xD;
&#xD;
          -  Subjects with the capacity to comprehend and understand her participation in this&#xD;
             clinical trial, manifested through informed consent form, even if with the help of&#xD;
             another person (Legal representative).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with chronic diseases (diabetes mellitus, neoplasia, renal failure,&#xD;
             tuberculosis) or any clinical and/or laboratory find (anamnesis, physical exam and/or&#xD;
             laboratory tests) that is interpreted, in the investigator's opinion, as a risk to the&#xD;
             subject's participation in the clinical trial;&#xD;
&#xD;
          -  Menopausal women;&#xD;
&#xD;
          -  Known hyper-sensibility to any of the products' components;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Subjects with active genital ulcer and/or with Genital herpes diagnosis;&#xD;
&#xD;
          -  Diagnosis or suspicion of Inflammatory pelvic disease;&#xD;
&#xD;
          -  Diagnosis of Vulvar condyloma acuminata;&#xD;
&#xD;
          -  Subjects under the usage of systemic corticosteroids for a period superior than 2&#xD;
             (two) months or under the usage of chemotherapeutics;&#xD;
&#xD;
          -  Transplanted subjects;&#xD;
&#xD;
          -  Subjects with history of active autoimmune diseases or with immune suppression;&#xD;
&#xD;
          -  Subjects under the usage of medication or therapy described on the protocol item&#xD;
             &quot;Prohibited Treatments&quot;;&#xD;
&#xD;
          -  Subjects that have participated on a clinical trial in the last 12 months (Conselho&#xD;
             Nacional de Saúde - Resolução 251, de 7 de agosto de 1997, item III, sub-item J),&#xD;
             unless the subject can have a direct benefit, in the investigator opinion;&#xD;
&#xD;
          -  Subject that have a kinship or bond with any employees of Sponsor or Research center;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo A. Junior, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scentryphar Pesquisa Clínica Ltda</affiliation>
  </overall_official>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaginal</keyword>
  <keyword>discharge</keyword>
  <keyword>women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Discharge</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clotrimazole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

